Breast cancer is the most prevalent cancer worldwide. With advancements in breast cancer diagnosis and treatment, the prognosis of patients with early-stage cancer has significantly improved. Enhancing the long-term quality of life of patients after antineoplastic therapy, including visual quality, has become a crucial research focus. This review aims to comprehensively summarize dry eye disease adverse reaction resulting from pharmacotherapy for early-stage breast cancer. Through a review of the relevant literature, this study explored the etiology, clinical features, and potential therapeutic strategies for drug-induced dry eye disease in breast cancer treatment. A thorough understanding of the medication-induced dry eye disease adverse reaction aid clinicians in monitoring and managing patients' ocular health more effectively, facilitating early diagnosis and intervention, preventing complications, and ensuring optimal visual protection for patients undergoing breast cancer treatment.

中文翻译：

---

干眼症早期乳腺癌药物治疗的不良反应


乳腺癌是全世界最普遍的癌症。随着乳腺癌诊断和治疗的进步，早期癌症患者的预后已显著改善。提高抗肿瘤治疗后患者的长期生活质量，包括视力质量，已成为一个重要的研究重点。本文旨在全面总结早期乳腺癌药物治疗引起的干眼症不良反应。通过对相关文献的回顾，本研究探讨了乳腺癌治疗中药物性干眼症的病因、临床特征和潜在的治疗策略。对药物诱导的干眼症不良反应的透彻了解有助于临床医生更有效地监测和管理患者的眼部健康，促进早期诊断和干预，预防并发症，并确保为接受乳腺癌治疗的患者提供最佳视觉保护。